Inverted GLP-1 injections: what the science says about technique claims

What did @thescholarsdesigns actually say?

The claim is simple: GLP-1 medications are available "in liquid form" and that this is good news for needle-phobic users. The creator frames this as a workaround, saying "here is in liquid form" while directing viewers to click somewhere, presumably to purchase or learn more about a product.

What the video does not say is nearly as important as what it does. There is no mention of which specific GLP-1 medication is being referenced, no dosing information, no regulatory status, and no clarification about whether this is a compounded product or an FDA-approved drug. That vagueness is doing a lot of work in a 132,000-view video. When you are talking about a drug class that includes semaglutide and tirzepatide, specificity is not optional. It is the whole ballgame.

Does the science back this up?

Partially, but the framing is misleading enough to be a real problem. FDA-approved GLP-1 receptor agonists approved for weight management, including semaglutide (Wegovy) and liraglutide (Saxenda), are subcutaneous injections. There is no FDA-approved oral GLP-1 specifically for weight loss that simply swaps a needle for a drink.

Oral semaglutide does exist. Rybelsus is an FDA-approved oral semaglutide tablet for type 2 diabetes, not weight management. It has strict administration requirements: taken on an empty stomach with no more than 4 oz of water, 30 minutes before eating. Davies et al. (2019, The Lancet) showed it reduced HbA1c effectively, but the bioavailability of oral semaglutide is roughly 1% compared to injectable forms, which is why the dosing structure is so demanding. Calling that a casual "liquid form" needle alternative is a stretch.

Some compounded pharmacies also offer oral or sublingual GLP-1 preparations. These are not FDA-approved and their bioavailability, safety, and efficacy data are not equivalent to approved injectables. The FDA has explicitly warned consumers about compounded semaglutide products multiple times in 2023 and 2024.

What did they get wrong (or right)?

They got the needle-aversion audience right. Needle phobia is real and clinically documented. Bech et al. (2019, Diabetes Technology and Therapeutics) found needle anxiety is a significant barrier to GLP-1 adherence. Acknowledging that barrier is legitimate.

What they got wrong is implying there is a seamless, equivalent liquid GLP-1 option waiting for you one click away. There is not, at least not an FDA-approved one for weight loss. Rybelsus exists but is for diabetes, has demanding administration requirements, and the weight loss data compared to injectable semaglutide is less robust. Wilding et al. (2021, NEJM) documented strong weight loss outcomes for injectable semaglutide in the STEP trials. No equivalent trial data exists for oral semaglutide in obesity treatment.

The "just click right here" call to action is the most concerning part. Directing a large audience toward an unnamed product, with no context about regulatory status, is exactly the pattern the FDA has flagged as a risk in the compounded GLP-1 market. This is not a minor omission. It is the kind of gap that puts people in danger.

What should you actually know?

If you have needle phobia and are exploring GLP-1 options, that conversation belongs with a licensed prescriber, not a TikTok video. Here is what is actually true right now. The only FDA-approved oral semaglutide is Rybelsus, indicated for type 2 diabetes management, not weight loss. Its administration protocol is strict and skipping those steps significantly reduces how much drug actually reaches your bloodstream.

Compounded oral or sublingual GLP-1 products exist in the market, but the FDA has explicitly not verified their safety, purity, or efficacy. The agency issued multiple safety communications in 2023 and 2024 warning about adverse events linked to compounded semaglutide, including dosing errors and contamination concerns.

Auto-injectors and pen devices used for injectable GLP-1 medications have also improved significantly and many patients with needle anxiety do adapt. That is worth discussing with a provider. The framing that oral equals safer or easier is not established by the clinical literature for this drug class. And any product that requires you to click a link on TikTok before you know what it is deserves serious scrutiny before you put it in your body.